Key Highlights
- FY26 audited results (1 July 2026, year to 31 March 2026) showed underlying operating profit of £12.6m, up 28.1%, even as group revenue fell 5.8% to £114.2m.
- Return on sales reached 11.0% and return on capital employed 29.1%, both clearing the prior turnaround plan's 10% and 25% targets ahead of schedule, prompting the launch of a new five-year 'Precision 2030' strategy.
- Precision 2030 targets compound annual revenue growth above 8%, net debt below 0.5 times EBITDA by FY31, and maintained minimum returns of 10% on sales and 25% on capital.
- Statutory operating profit rose 61.8% to £12.3m, and profit before tax jumped around 79% to £4.8m from £2.7m; underlying EPS edged down to 4.1p from 4.3p.
- Operating cash generation fell to £12.0m from £19.1m as working capital swung to a £6.3m outflow, and net debt rose to £23.9m from £19.2m, leaving gearing at 1.3 times EBITDA; no dividend was proposed.
- The group carries a defined-benefit pension liability of £46.8m (IAS 19 basis) with a technical-provisions deficit of £52.9m requiring rising cash contributions, stepping up to £5.8m a year from March 2029.
A Balancing Act Between Margin and Volume
Carclo, the Yorkshire-based precision plastics and technology group, has delivered a set of full-year figures that neatly captures the balancing act facing many small-cap industrials: revenue slipped, but profitability climbed sharply and management arrived at its medium-term margin goals a year or more ahead of plan. In its audited results for the year to 31 March 2026, published on 1 July, the company reported underlying operating profit of £12.6m, up 28.1% on the prior year, even as group revenue fell 5.8% to £114.2m.
The wider significance lies less in a single year's numbers than in what they signal. Reaching a 10% return on sales and a 25% return on capital employed early has given the board the confidence to launch a fresh five-year plan, branded Precision 2030, aimed at shifting the emphasis from margin repair to organic growth.
A Precision Manufacturer Serving Healthcare and Aerospace
Carclo has its roots in the West Yorkshire textile trade but today operates as a precision manufacturing group. Its principal business, Carclo Technical Plastics (CTP), designs and produces high-specification injection-moulded components, largely for the medical diagnostics and drug-delivery markets, alongside optics and other technical applications. Manufacturing sites span the UK, North America, China, India and the Czech Republic. Alongside CTP sits a smaller Speciality arm, which houses the group's aerospace connector and lighting activities — modest in revenue terms but carrying higher margins and long qualification cycles that make customer relationships sticky.
Margin Targets Hit Ahead of Schedule
The event driving the numbers is twofold: a demonstrable step-up in profitability, and the formal unveiling of the Precision 2030 strategy. The company reported that return on sales reached 11.0% and return on capital employed 29.1%, both comfortably clearing the 10% and 25% targets set under the previous turnaround plan and reached, in management's words, ahead of schedule. Precision 2030 sets out organic ambitions: a compound annual revenue growth rate above 8%, net debt reduced to below 0.5 times EBITDA by FY31, and the maintenance of minimum returns of 10% on sales and 25% on capital. The plan leans on expanding into adjacent markets such as drug delivery, pharmaceutical packaging and wearables.
The Financials in Detail
Statutory measures moved further than the underlying figures. Statutory operating profit rose 61.8% to £12.3m, while profit before tax jumped to £4.8m from £2.7m, a rise of around 79%. Profit after tax reached £2.7m against £0.9m, lifting basic earnings per share to 3.7p from 1.2p. Underlying earnings per share, by contrast, edged down to 4.1p from 4.3p, a reminder that the profit gains flow partly from cost and mix improvements rather than volume. Underlying EBITDA rose 13.6% to £18.6m, and divisional margins tell the clearer story: CTP's operating margin widened to 15.4% from 11.6%, and Speciality's to 22.4% from 19.7%. The trade-off appeared in cash: operating cash generation fell to £12.0m from £19.1m as working capital swung to a £6.3m outflow, and net debt rose to £23.9m from £19.2m, leaving gearing at 1.3 times EBITDA. The board proposed no dividend.
Lower Revenue, Higher Quality Earnings
Revenue of £114.2m compares with £121.2m, with CTP down 8.2% to £98.2m, dragged partly by a 28.2% fall in the Design & Engineering sub-segment. Speciality bucked the trend, growing 12.5% to £16.0m and delivering record aerospace orders for a third consecutive year. Margin progression is the standout when measured over the plan's life, though the softer cash conversion, at 65.6% versus an unusually strong 135% a year earlier, and the higher net debt mean the improvement isn't uniform across every metric.
The Pension Deficit and Trading Risks
The balance sheet remains the central watch item. Net debt of £23.9m sits against a market capitalisation of roughly £25m, and the group carries a defined-benefit pension liability of £46.8m on an IAS 19 basis, with a technical-provisions deficit of £52.9m requiring rising cash contributions, stepping up to £5.8m a year from March 2029. Quarterly covenant testing under the £36m BZ Commercial Finance facility adds a further constraint, though the company confirmed full compliance through FY26. Trading conditions are described as mixed, with a notably weaker respiratory virus season softening diagnostics demand, which management expects to be temporary.
Outlook
Carclo's FY2026 results show a company that has, on its own metrics, done what it set out to do on profitability, hitting margin and return targets ahead of schedule and using that platform to reset ambitions towards growth. The 28% rise in underlying operating profit against falling revenue underscores a genuine improvement in earnings quality. The counterweight is a stretched balance sheet, a sizeable pension obligation and softer cash generation, all of which leave limited margin for error. The investment question is not whether the turnaround has delivered so far, but whether Precision 2030 can add organic growth without straining the group's finances.






Please wait processing your request...